Cargando…
Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort
Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormaliti...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305461/ https://www.ncbi.nlm.nih.gov/pubmed/35150056 http://dx.doi.org/10.1111/bcpt.13715 |
_version_ | 1784752331126996992 |
---|---|
author | Schoretsanitis, Georgios Dubath, Céline Grosu, Claire Piras, Marianna Laaboub, Nermine Ranjbar, Setareh Ansermot, Nicolas Crettol, Séverine Vandenberghe, Frederik Gamma, Franziska von Gunten, Armin Plessen, Kerstin Jessica Seifritz, Erich Conus, Philippe Eap, Chin B. |
author_facet | Schoretsanitis, Georgios Dubath, Céline Grosu, Claire Piras, Marianna Laaboub, Nermine Ranjbar, Setareh Ansermot, Nicolas Crettol, Séverine Vandenberghe, Frederik Gamma, Franziska von Gunten, Armin Plessen, Kerstin Jessica Seifritz, Erich Conus, Philippe Eap, Chin B. |
author_sort | Schoretsanitis, Georgios |
collection | PubMed |
description | Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed‐effects logistic regression models. In 392 olanzapine‐treated patients (median age 38.0 years, interquartile range [IQR] = 26.0–53.3, median dose 10.0 mg/day, IQR = 5.0–10.0 for a median follow‐up duration of 40.0 days, IQR = 20.7–112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co‐prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain (p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure (p < 0.05), whereas higher doses were associated with glucose increases (p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57–2.97). EWG might be prominent in high‐dose olanzapine‐treated patients with treatment duration and co‐prescription of other medications being weight gain moderators. The lack of major dose‐dependent patterns for weight gain emphasizes that olanzapine‐treated patients are at weight gain risk regardless of the dose. |
format | Online Article Text |
id | pubmed-9305461 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-93054612022-07-28 Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort Schoretsanitis, Georgios Dubath, Céline Grosu, Claire Piras, Marianna Laaboub, Nermine Ranjbar, Setareh Ansermot, Nicolas Crettol, Séverine Vandenberghe, Frederik Gamma, Franziska von Gunten, Armin Plessen, Kerstin Jessica Seifritz, Erich Conus, Philippe Eap, Chin B. Basic Clin Pharmacol Toxicol Clinical Pharmacology Metabolic abnormalities have been associated with olanzapine treatment. We assessed if olanzapine has dose‐dependent effects on metabolic parameters with changes for weight, blood pressure, lipid and glucose profiles being modelled using linear mixed‐effects models. The risk of metabolic abnormalities including early weight gain (EWG) (≥5% during first month) was assessed using mixed‐effects logistic regression models. In 392 olanzapine‐treated patients (median age 38.0 years, interquartile range [IQR] = 26.0–53.3, median dose 10.0 mg/day, IQR = 5.0–10.0 for a median follow‐up duration of 40.0 days, IQR = 20.7–112.2), weight gain was not associated with olanzapine dose (p = 0.61) although it was larger for doses versus ≤10 mg/day (2.54 ± 5.55 vs. 1.61 ± 4.51% respectively, p = 0.01). Treatment duration and co‐prescription of >2 antipsychotics, antidepressants, benzodiazepines and/or antihypertensive agents were associated with larger weight gain (p < 0.05). Lower doses were associated with increase in total and HDL cholesterol and systolic and diastolic blood pressure (p < 0.05), whereas higher doses were associated with glucose increases (p = 0.01). Patients receiving >10 mg/day were at higher EWG risk (odds risk: 2.15, 1.57–2.97). EWG might be prominent in high‐dose olanzapine‐treated patients with treatment duration and co‐prescription of other medications being weight gain moderators. The lack of major dose‐dependent patterns for weight gain emphasizes that olanzapine‐treated patients are at weight gain risk regardless of the dose. John Wiley and Sons Inc. 2022-02-17 2022-04 /pmc/articles/PMC9305461/ /pubmed/35150056 http://dx.doi.org/10.1111/bcpt.13715 Text en © 2022 The Authors. Basic & Clinical Pharmacology & Toxicology published by John Wiley & Sons Ltd on behalf of Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Clinical Pharmacology Schoretsanitis, Georgios Dubath, Céline Grosu, Claire Piras, Marianna Laaboub, Nermine Ranjbar, Setareh Ansermot, Nicolas Crettol, Séverine Vandenberghe, Frederik Gamma, Franziska von Gunten, Armin Plessen, Kerstin Jessica Seifritz, Erich Conus, Philippe Eap, Chin B. Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
title | Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
title_full | Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
title_fullStr | Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
title_full_unstemmed | Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
title_short | Olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
title_sort | olanzapine‐associated dose‐dependent alterations for weight and metabolic parameters in a prospective cohort |
topic | Clinical Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305461/ https://www.ncbi.nlm.nih.gov/pubmed/35150056 http://dx.doi.org/10.1111/bcpt.13715 |
work_keys_str_mv | AT schoretsanitisgeorgios olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT dubathceline olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT grosuclaire olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT pirasmarianna olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT laaboubnermine olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT ranjbarsetareh olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT ansermotnicolas olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT crettolseverine olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT vandenberghefrederik olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT gammafranziska olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT vonguntenarmin olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT plessenkerstinjessica olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT seifritzerich olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT conusphilippe olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort AT eapchinb olanzapineassociateddosedependentalterationsforweightandmetabolicparametersinaprospectivecohort |